Enfortumab Vedotin combined with Pembrolizumab will now be available for eligible patients in the UK
The British Association of Urological Surgeons (BAUS) welcomes the decision by the National Institute for Health and Care Excellence (NICE) to approve the use of combination therapy enfortumab vedotin (Padcev) with pembrolizumab as a first-line... Read more
22 Aug 2025